The uPA/uPA receptor system as a target for tumor therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Tumor invasiveness relies on proteolytic enzymes degrading the extracellular matrix.
• The urokinase-type plasminogen activator (uPA) system is crucial for tumor cell invasion and metastasis.
• This system comprises uPA, its receptor uPAR (CD87), and inhibitors PAI-1/PAI-2.

Purpose of the Study:

• To explore the therapeutic relevance of targeting the uPA system in cancer.
• To investigate strategies for inhibiting uPA enzymatic activity and/or uPAR binding.
• To leverage structural information for drug design against uPA.

Main Methods:

• Utilizing X-ray crystallography of uPA/inhibitor complexes to guide drug optimization.
• Designing peptide compounds that mimic uPA epitopes to antagonize receptor binding.
• Evaluating the potential of inhibiting uPA and uPAR interactions.

Main Results:

• X-ray structures provide a basis for enhancing affinity and selectivity of uPA inhibitors.
• Peptide-based antagonists effectively block the uPA-uPAR recognition process.
• Both inhibition strategies show promise for therapeutic applications.

Conclusions:

• Interference with the uPA system holds significant therapeutic potential for cancer treatment.
• Structural insights facilitate the optimization of existing lead compounds for uPA inhibition.
• Peptide mimetics offer a viable approach for designing drugs that target uPA-receptor interactions.